Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis

Gene Therapy

Volumn 19, Issue 2, 2012, Pages 210-218

  Uhrig, S ^a,b   Coutelle, O ^a,b   Wiehe, T ^b   Perabo, L ^a   Hallek, M ^a,b   Buning H ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

AAV cell surface targeting; internalization pathway; intracellular fate

Indexed keywords

CAVEOLIN; CLATHRIN; PARVOVIRUS VECTOR; PROTEOHEPARAN SULFATE;

ARTICLE; BINDING AFFINITY; ENDOCYTOSIS; GENE INSERTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS MUTANT; VIRUS RECOMBINANT;

CAPSID PROTEINS; CLATHRIN; DEPENDOVIRUS; ENDOCYTOSIS; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HELA CELLS; HEP G2 CELLS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MUTAGENESIS, INSERTIONAL; MUTATION; TRANSDUCTION, GENETIC; VIRUS INTERNALIZATION;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 84856953535     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.78     Document Type: Article

References (45)

1. Büning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med 2008; 10: 717-733. (Pubitemid 352003915)
2. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 2009; 119: 1688-1695.
3. Kwon I, Schaffer DV. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 2007; 25: 489-499.
4. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-327. (Pubitemid 44184972)
5. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445. (Pubitemid 28116931)
6. Kern A, Schmidt K, Leder C, Muller OJ, Wobus CE, Bettinger K et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 2003; 77: 11072-11081. (Pubitemid 37204297)
7. Opie SR, Warrington Jr KH, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 2003; 77: 6995-7006. (Pubitemid 36666892)
8. Boucas J, Lux K, Huber A, Schievenbusch S, von Freyend MJ, Perabo L et al. Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations. J Gene Med 2009; 11: 1103-1113.
9. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Adenoassociated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 2006; 80: 8961-8969. (Pubitemid 44359970)
10. Sanlioglu S, Benson PK, Yang J, Atkinson EM, Reynolds T, Engelhardt JF. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 2000; 74: 9184-9196.
11. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82. (Pubitemid 29051002)
12. Perabo L, Goldnau D, White K, Endell J, Boucas J, Humme S et al. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 2006; 80: 7265-7269. (Pubitemid 44025223)
13. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003; 7: 515-525. (Pubitemid 36553421)
14. Marsh M, Helenius A. Virus entry: open sesame. Cell 2006; 124: 729-740. (Pubitemid 43261448)
15. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993; 123: 1107-1117. (Pubitemid 23352421)
16. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999; 73: 10371-10376.
17. Pellinen T, Ivaska J. Integrin traffic. J Cell Sci 2006; 119 (Part 18): 3723-3731. (Pubitemid 44614425)
18. Payne CK, Jones SA, Chen C, Zhuang X. Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic 2007; 8: 389-401. (Pubitemid 46421621)
19. Van Hamme E, Dewerchin HL, Cornelissen E, Verhasselt B, Nauwynck HJ. Clathrin-and caveolae-independent entry of feline infectious peritonitis virus in monocytes depends on dynamin. J Gen Virol 2008; 89 (Part 9): 2147-2156.
20. Bantel-Schaal U, Braspenning-Wesch I, Kartenbeck J. Adeno-associated virus type 5 exploits two different entry pathways in human embryo fibroblasts. J Gen Virol 2009; 90 (Part 2): 317-322.
21. Shayakhmetov DM, Eberly AM, Li ZY, Lieber A. Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol 2005; 79: 1053-1061. (Pubitemid 40053889)
22. Denby L, Nicklin SA, Baker AH. Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Therapy 2005; 12: 1534-1538. (Pubitemid 41508679)
23. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adenoassociated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 2001; 75: 1824-1833. (Pubitemid 32110172)
24. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105: 1573-1587. (Pubitemid 30390308)
25. Kopatz I, Remy JS, Behr JP. A model for non-viral gene delivery: through syndecan adhesion molecules and powered by actin. J Gene Med 2004; 6: 769-776. (Pubitemid 40228093)
26. Ogris M, Wagner E. Targeting tumors with non-viral gene delivery systems. Drug Discov Today 2002; 7: 479-485. (Pubitemid 34532575)
27. Multhaupt HA, Yoneda A, Whiteford JR, Oh ES, Lee W, Couchman JR. Syndecan signaling: when, where and why? J Physiol Pharmacol 2009; 60 (Suppl 4): 31-38.
28. Liang M, Morizono K, Pariente N, Kamata M, Lee B, Chen IS. Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway. J Virol 2009; 83: 13026-13031.
29. Mudhakir D, Akita H, Tan E, Harashima H. A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway. J Control Rel 2008; 125: 164-173. (Pubitemid 350299613)
30. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713. (Pubitemid 28520834)
31. Kircheis R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T et al. Coupling of cellbinding ligands to polyethylenimine for targeted gene delivery. Gene Therapy 1997; 4: 409-418. (Pubitemid 27226583)
32. Kreppel F, Gackowski J, Schmidt E, Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de-and retargeting of adenovirus vectors. Mol Ther 2005; 12: 107-117. (Pubitemid 40862362)
33. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans 2005; 33 (Part 5): 891-895. (Pubitemid 41659073)
34. Kronenberg S, Bottcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol 2005; 79: 5296-5303. (Pubitemid 40548198)
35. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 2006; 80: 11040-11054. (Pubitemid 44706545)
36. Stahnke S, Lux K, Uhrig S, Kreppel F, Hosel M, Coutelle O et al. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology 2010; 409: 77-83.
37. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene Therapy 2005; 12: 873-880. (Pubitemid 40852205)
38. Shayakhmetov DM, Li ZY, Ternovoi V, Gaggar H, Gharwan H, Lieber A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 2003; 77: 3712-3723. (Pubitemid 36297290)
39. Perabo L, Büning H, Kofler DM, Ried MU, Girod A, Wendtner CM et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003; 8: 151-157. (Pubitemid 36939306)
40. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181. (Pubitemid 32851280)
41. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232. (Pubitemid 28100780)
42. Hacker UT, Gerner FM, Büning H, Hutter M, Reichenspurner H, Stangl M et al. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adenoassociated virus type 2 vectors. Gene Therapy 2001; 8: 966-968. (Pubitemid 32600154)
43. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5: 1052-1056. (Pubitemid 29439578)
44. Theiss HD, Kofler DM, Büning H, Aldenhoff AL, Kaess B, Decker T et al. Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides. Exp Hematol 2003; 31: 1223-1229. (Pubitemid 37510027)
45. Mizukami H, Young NS, Brown KE. Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology 1996; 217: 124-130. (Pubitemid 26103603)